Affymetrix Names GenoSplice as Its Preferred Data Analysis Service Provider Increasing Accessibility for Bioinformatics in Ge...
March 06 2013 - 6:30AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) announced a co-marketing
agreement today naming GenoSplice, Inc. as its preferred data
analysis service provider for the new GeneChip® Human Transcriptome
Array 2.0, the most comprehensive microarray available for
alternative splicing detection. GenoSplice, a leader in genomic
data analysis and alternative splicing, has developed a dedicated
expression analysis solution, EASANA®, including analysis for
Affymetrix’ microarrays, such as GeneChip® Exon 1.0 ST Array,
GeneChip® Human Transcriptome Array 1.0, and the new GeneChip®
Human Transcriptome Array 2.0. When combined with GenoSplice
analysis services, these arrays provide the highest resolution
profiling of the transcriptome available on a microarray at both
the gene and exon level.
“As part of Affymetrix’ commitment to provide end-to-end
solutions, we are enabling those without access to bioinformatics
to utilize the most powerful microarrays ever developed for the
interrogation of alternative splicing events. Now with so many
options open to researchers, it is increasingly more important to
provide tools that generate biologically relevant results, not just
data,” commented Kevin Cannon, SVP – Expression Business Unit at
Affymetrix.
“We’re pleased to work with Affymetrix to combine two very
powerful tools, Affymetrix’ high resolution microarrays for gene
expression profiling of transcript isoforms and GenoSplice’s
proprietary transcriptome data analysis service, to help
researchers save valuable time so they can focus on the biology
instead of on analytical details,” said Marc Rajaud, Co-CEO of
GenoSplice. “GeneChip® Human Transcriptome Array 2.0 increases
accessibility to genomic research, resulting in new data that have
to be interpreted to be useful. Collaborating with Affymetrix helps
keep GenoSplice on the forefront of developing dedicated tools that
streamline and simplify genomic data analysis.”
PLEASE NOTE: Affymetrix®, the Affymetrix logo, and
GeneChip® trademarks are the property of Affymetrix, Inc. All other
trademarks are the property of their respective owners.
Products mentioned in this release are For Research Use only.
Not for diagnostic procedures.
SOURCE: Affymetrix, Inc.
About GenoSplice
GenoSplice develops and globally markets unique high level
bioinformatics analysis services for genomics data. The company
provides in-house innovative solutions for integrated genomics and
is unique in offering user-friendly support and long-term
relationship for all next generation sequencing and microarray
platforms. Each client as each analysis is unique. GenoSplice
services mainly concern differential gene expression, alternative
splicing, miRNA, fusion transcript, epigenetics, SNP, CNV,
translocation and proteomics data. Visit www.genosplice.com for
additional information.
About Affymetrix
Affymetrix technologies are used by the world's top
pharmaceutical, diagnostic, and biotechnology companies, as well as
leading academic, government, and nonprofit research institutes.
More than 2,300 microarray systems have been shipped around the
world and more than 48,000 peer-reviewed papers have been published
citing our technologies. Affymetrix is headquartered in Santa
Clara, California, and has manufacturing facilities in Cleveland,
Ohio, and Singapore. eBioscience is headquartered in San Diego,
California and has manufacturing facilities in San Diego and
Vienna, Austria. Including eBioscience, the Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2011, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024